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peutic intervention and trial monitoring and outcome evaluation. Complicating
this situation is inconsistencies in CFS case definition. The main objective is to
provide a critical review of the similarities and differences between the varying
approaches to CFS case definition. The conflicts and controversies that have
emerged as a result of the differing definitional criterion for CFS are highlighted
and the potential impact on future research is identified. A critical review of the
most frequently used case definitions in CFS was conducted. There are currently
five case definitions of CFS; however, the most prominent is the 1994 Centre for
Disease Control and PreventionCaseDefinitions. However, prima face comparative
advantages of this definition are elusive and indeed, it has been widely criticized
for its lack of specificity. Counterintuitively, there is little compelling evidence to
support the efficacy of any of the case definitions have produced evidence to dem-
onstrate their accuracy or precision at defining cases of CFS. A summary descrip-
tion of the symptom profile for each of the case definitions is provided. The incon-
sistencies that have emerged in CFS research as a consequence of differing
approaches to case definition are contrasted and discussed. Clinical and research
implications are highlighted.
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IQWIG AND HIQA, WHAT ARE THEY GOOD FOR? THE EVOLUTION OF THE HTA
AGENCY: TIME FROM CREATION TO FIRST ASSESSMENT AND IMPACTFUL
APPRAISAL
Green MJ
HERON Evidence Development LLC, Somerville, NJ, USA
OBJECTIVES: To evaluate the time spent from the creation or charter of an HTA
agency to endpoints indicating their effectiveness, such as publication of assess-
ments and evidence of the incorporation of assessment into meaningful appraisal
influencing patient access to health technologies. METHODS: This study looks at
the creation ofHTAagencies (e.g. AHRQ,HIQA, IQWiG, PBAC, CADTHandNICE) and
their evolution in terms of roles in assessment (advisory, coordinating, decision-
making) and the relationship they have with appraisal. RESULTS: It has been dem-
onstrated that the time it takes for an agency to generate assessments impacting
patient access varies widely. For example, in Ireland, HIQA was chartered in May
2007, and entrustedwith performingHTA assessments. In 2008 and 2009, HIQA has
published one health technology assessment per year, both ofwhichwere received
and in turn implemented by the Minister for Health and Children. In comparison,
NICE in the UK was founded in 1999, but its appraisals were not supported by
mandate until 2005. Meanwhile, HTAs driven by DAHTA@DIMDI in Germany are
known to rarely play a role in pricing and reimbursement. CONCLUSIONS: The
evolution of HTA bodies has varied from country to country. However, evolution in
scope and impact may provide useful lessons for countries where HTA is receiving
renewed emphasis or where appraisal is under consideration for implementation,
especially as new agencies are created and existing agencies evolve.
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OPTIMIZING THE ORGANIZATION; MIGRATING HEALTH SERVICES RESEARCH
OPERATIONS INTO THE COLLABORATIVE SCIENCE CENTER OF EXCELLENCE
Benson J, Enterline L
Bristol-Myers Squibb, Plainsboro, NJ, USA
The execution and management of Health Services Research projects can be an
onerous task. Often there is no centralized body of knowledge within an organiza-
tion around process and requirements. This leads to long execution timelines,
difficulties with vendors and ultimately reduced productivity. The Collaborative
Science Center of Excellence (CSCoE) was established in 2008 at Bristol-Myers
Squibb (BMS). This group manages the global operations of a wide variety of pro-
grams, a portion of which includes worldwide investigator sponsored research,
non-clinical research, expanded access, and risk evaluation and mitigation pro-
grams. Beginning June 2009, operational management of the entire US Health Eco-
nomics and Outcomes Research (HEOR) book of work was moved from the OR
Scientists into the CSCoE. This included administration, contract execution, mas-
ter service agreement negotiation, financial management, protocol writing, AMCP
dossier updates, and invoice tracking and payment. Within the first year over 90
projectsweremigrated into the CSCoE. Benefits theHealth Services Research group
realized included: 1. A consolidated 2010 and planned 2011 book of work; 2. A
reportable repository of project information; 3. HEOR protocol and AMCP dossier
improvement through standardization of in-house scientific writing; 4. Expedited
contract execution; 5. Innovative cost-sharing; 6. Tiered and batched review of
contracts reduced corporate legal hours; 7. Rapid response to organizational que-
ries. Centralized process management unlocked latent value by allowing OR Sci-
entists to focus on value-added activities, increased organizational transparency
and agility, and moved operations to a lower cost environment.
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OBJECTIVES: To evaluate the risk of developing venous thromboembolism (VTE)
events associated with the use of estradiol transdermal system (ETS; Vivelle-Dot®)
relative to oral estrogen-only hormone therapy (HT) agents. METHODS: A health
insurance claims analysis was conducted using the Thomson Reuters MarketScan
database from January 2002 through October 2009. Patients 35 years old newly
initiated on an ETS or oral estrogen-only HT with 2 dispensings were analyzed.
VTE was defined as 1 diagnosis code for deep vein thrombosis or pulmonary
embolism. As a secondary outcome we assessed incident VTE resulting in hospi-
talization. Cohorts of ETS and oral estrogen-only HT were matched 1:1 based on
both exact factor and propensity score matching. Incidence rate ratio (IRR) was
used to compare the rates of VTE between the matched cohorts. Remaining base-
line imbalances from matching were included as covariates in multivariate
adjustments. RESULTS: Among the matched ETS and oral estrogen-only HT users
(27,018 subjects in each group), the mean (SD) ages of the cohorts were 48.9 (7.1)
years; in each cohort 6,044 (22.4%) and 1,788 (6.6%) patients had ahysterectomyand
an oophorectomy at baseline, respectively. The mean (median) drug exposure for
the ETS and oral estrogen-only HT cohorts was 391 (264) and 401 (272) days, respec-
tively. A total of 115 ETS users developed VTE compared to 164 subjects in the
estrogen-only HT cohort (unadjusted IRR: 0.72; 95% CI: 0.57-0.91, P0.006). After
adjustments, ETS remained statistically significantly associated with a lower inci-
dence (33% reduction; P0.0134) of VTE. The incidence rate reduction for hospital-
ization-related VTE events among the ETS users was even more pronounced with
the adjusted incidence being 62% lower for ETS users relative to oral estrogen-only
HTusers.CONCLUSIONS:Results of this large population-based study showed that
patients receiving ETS had a significantly lower incidence of VTE compared to
patients receiving oral estrogen-only HT.
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THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIETARY
CALCIUM AND VITAMIN D SUPPLEMENTS IN PATIENTS WITH OSTEOPOROSIS
Chang JY1, Nichol MB2
1University of Southern California, Alhambra, CA, USA, 2University of Southern California, Los
Angeles, CA, USA
OBJECTIVES: Calcium and vitamin D supplements have been widely used and
recommended forwomen to prevent or delay the onset of osteoporosis and the risk
of bone fractures. Other benefits include the improvement of blood pressure and
lipid levels and a lowering of body weight. In theory, the beneficial effects of cal-
cium and vitamin D suggest improvements in cardiovascular health. Recent pub-
lications suggest the contrary and allude to increase serum calcium as a risk factor
for adverse cardiovascular events. This study examines whether the exposure to
these supplements are associated with cardiovascular events. METHODS: The
study was based on California Medicaid (Medi-Cal) fee-for-service administrative
claims data from January 1995 to December 2002. The study population consist of
patients50 years with recorded diagnoses of osteoporosis followed from diagno-
ses date to the end of eligibility. Patients were excluded for prior use of the supple-
ments or diagnosis of cardiovascular events or drug induced osteoporosis. Propen-
sity score matching based on age, gender, elixhauser comorbidities and eligibility
data created case (n 1594) and control groups (n4782). Chi-square analysis was
conducted for comparison of the cardiovascular events defined as ICD9 codes for
myocardial infarction and searchable terms of “cerebral infarction, hemorrhage,
ischemia” for stroke. RESULTS: No statistically significant relationship was found
between the study groups for stroke (p0.56) and myocardial infarction (p0.54).
Components of stroke included cerebral artery occlusion (p0.94), precerebral ar-
tery occlusion (p0.27), intracerebral hemorrhage (p0.23), and subarachnoid
hemorrhage (p0.05). The clinical benefits of the supplements were evident with
subarachnoid hemorrhage with 0 recorded diagnoses in the case group compared
to 12 recorded diagnosis in the control group; however statistical significance was
not established. CONCLUSIONS: The use of calcium and vitamin D supplementa-
tion yielded no relationship to the risk of adverse cardiovascular events. Moreover,
no broad cardio-protective effects can be concluded from the study.
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RISK OF HOSPITALIZATIONS FOR VENOUS THROMBOEMBOLISM IN ATYPICAL
VERSUS TYPICAL ANTIPSYCHOTIC USERS IN A NATIONAL SAMPLE OF
MEDICARE BENEFICIARIES: A CLAIMS DATA ANALYSIS
Dharmarajan SH, Yang Y, Athavale AS, Bentley JP, Null KD, Banahan BF
University of Mississippi, University, MS, USA
OBJECTIVES:To examine the difference between typical and atypical antipsychotic
drug use in the risk of hospitalization for venous thromboembolism (VTE) in an
elderly Medicare population.METHODS: This is a retrospective cohort study using
5%national sample of 2006-2007Medicare claims data. Medicare beneficiarieswith
continuous Part A, B, and D enrollment in 2006-2007 and who initiated atypical or
typical antipsychotic drug therapy in July 2006-June 2007 were included. All study
subjects were followed for a period of 180 days from the date of index prescription.
Atypical and typical users were matched on propensity score, calculated using
pre-index demographics, clinical comorbidities, andmedication use. A conditional
logistic regressionmodel stratified on the propensity score-matched pair using the
Greedymatching algorithmwas used to compare the risk of hospitalization for VTE
in new users of atypical and typical antipsychotic drugs. Sensitivity analysis in the
unmatched cohort was performed using propensity score as a continuous, linear
term in logistic regression. RESULTS: A total of 15,637 new users of atypical and
2,337 new users of typical antipsychotic drugs were identified. There were 472
(2.6%) individuals with a hospitalization for VTE during follow-up. 417 were atyp-
ical and 55 were typical antipsychotic users. A 1:1 propensity score match yielded
2,333 matched pairs (4,666 individuals). In the matched cohort, 55 typical and 64
atypical drug users were hospitalized for VTE in the follow up period. Compared to
typical antipsychotic users, users of atypical antipsychoticswere less likely to have
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